Anastrozole Arimidex Anti Estrogen Steroids ISO9001 CAS 120511-73-1

Powerful Anti-Estrogen Pharmaceutical Grade Anastrozole / Arimidex Raw Powder

Description:

Anastrozole is also called Arimidex, it can be referred to as an aromatase inhibitor which helps

prevent estrogen production in females. Research has shown that the estrogen hormone is

responsible for the creation of breast cancer tumors in women. Arimidex is the drug administered

to intercept the enzyme aromatase, which is a substance that assists the body tissues in

producing estrogen. Arimidex is a popular drug in the battle against breast cancer. It is by and

large, a hormonal treatment which can prevent the recurrence of breast cancer.

Arimidex is known to have diminished estrogen way too much in some patients. This is why blood

tests or salivary tests are recommended after a week of usage to determine whether the dosage

is appropriate.

Arimidex tends to work quite differently than the traditional anti-estrogens. Anti-estrogens like

Clomid or Nolvadex tend to intercept estrogen receptors in certain tissues while activating them

in others. Meanwhile, Arimidex directly intercepts the enzyme aromatase. When a patient has

been recommended the use of Arimidex, Clomid use along with is unnecessary. Doing so may

have some benefits.

Arimidex is generally used for all stages and forms of breast cancer which are classified to be

estrogen receptor positive. In case the patient has estrogen receptor negative or triple negative

cancer, the usage of Arimidex is unlikely to help.

Lab Test Result:

Application:

An aromatase inhibitor. Used as an antineoplastic raw materials.

Potent selective triazole aromatase inhibitors, can inhibit the cytochrome P-450 aromatase

enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast

cancer cell growth factors. Treatment of breast cancer, especially for those with hormone relapse

after adjuvant therapy after menopause for women with advanced breast cancer.

The drug is appropriately used when using substantial amounts of aromatizing steroids, or when

one is prone to gynecomastia and using moderate amounts of such steroids. Arimidex does not

have the side effects of aminoglutethimide (Cytadren) and can achieve a high degree of estrogen

blockade, much moreso than Cytadren. It is possible to reduce estrogen too much with Arimidex,

and for this reason blood tests, or less preferably salivary tests, should be taken after the first

week of use to determine if the dosing is correct.

Dosage:

Dosages of arimidex will vary from person to person. This is why blood work is essential to

finding the perfect balance. One should start out at half a mg every other day and adjust as

needed for the cycle. Some AAS users will not use an AI at first but they will have it on hand just in

case. This isn't always a good idea, as once you start noticing gyno or excessive water weight it

could be too late to reverse. Since AAS will continue building in the body and aromatize, taking

arimidex at this point would be like trying to stop a car already in motion.

General dosage for men: 0.5 mg per day or every other day

Anastrozole VS Letrozole

Aromatase inhibition is the gold standard for treatment of early and advanced breast cancer in

postmenopausal women suffering from an estrogen receptor-positive disease. The currently

established group of anti-aromatase compounds comprises two reversible aromatase inhibitors

(anastrozole and letrozole) and on the other hand, the irreversible aromatase inactivator

exemestane. Although exemestane is the only widely used aromatase inactivator at this stage,

physicians very often have to choose between either anastrozole or letrozole in general practice.

These third-generation aromatase inhibitors Letrozole and Anastrozole, have recently

demonstrated superior efficacy compared with tamoxifen as initial therapy for early breast cancer

improving disease-free survival. However, although anastrozole and letrozole belong to the same

pharmacological class of agents (triazoles), an increasing body of evidence suggests that these

aromatase inhibitors are not equipotent when given in the clinically established doses. Preclinical

and clinical evidence indicates distinct pharmacological profiles. Thus, this review focuses on the

differences between the non-steroidal aromatase inhibitors allowing physicians to choose

between these compounds based on scientific evidence. Although we are waiting for the

important results of a still ongoing head-to-head comparison in patients with early breast cancer

at high risk for relapse, clinicians have to make their choices today. On the basis of available

evidence summarised here and until FACE-data become available, letrozole seems to be the

best choice for the majority of breast cancer patients whenever a non-steroidal aromatase

inhibitor has to be chosen in a clinical setting.

Contact: Allen

Whatsapp:+8618971485175

Email:allenraws0437@gmail.com